- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00706797
Study Evaluating Efficacy / Safety of Etanercept + Methotrexate Compared to Usual Treatment in Moderate RA Subjects
June 16, 2011 updated by: Wyeth is now a wholly owned subsidiary of Pfizer
An Open-Label, Randomized Study to Evaluate the Radiographic Efficacy and Safety of Enbrel™ (Etanercept) Added to Methotrexate in Comparison With Usual Treatment in Subjects With Moderate Rheumatoid Arthritis Disease Activity
To assess comparative radiographic efficacy, clinical efficacy and safety of etanercept (ETN) + methotrexate (MTX) with usual disease-modifying anti-rheumatic drug (DMARD) treatment in subjects with moderate RA who were treated with MTX monotherapy, but continue to have moderate disease activity.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
141
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Ostrava, Czech Republic, 722 00
-
Prague, Czech Republic, 128-50
-
Prague, Czech Republic, 140-59
-
-
-
-
-
Amiens, France, 80054
-
Amiens cedex 1, France, 80054
-
Echirolles, France, 38130
-
Metz, France, 57077
-
Montpellier, France, 34295
-
Paris, France, 75651
-
Paris, France, 75679
-
Paris cedex 13, France, 75651
-
Paris cedex 14, France, 75679
-
Rouen, France, 76031
-
Tours, France, 37044
-
Tours cedex 9, France, 37044
-
-
-
-
-
Berlin, Germany, 10117
-
Frankfurt, Germany, 60590
-
Hamburg-Eilbeck, Germany, 22081
-
Homburg, Germany, 66424
-
Koeln, Germany, 50924
-
Mainz, Germany, 55131
-
-
-
-
-
Budapest, Hungary, 1036
-
Budapest, Hungary, 1023
-
Miskolc, Hungary, 3529
-
Rijeka, Hungary, 51000
-
Split, Hungary, 21000
-
Zagreb, Hungary, 10000
-
-
-
-
-
Jesi (Ancona), Italy, 60035
-
Reggio Calabria, Italy, 89100
-
-
-
-
-
Bytom, Poland, 41-902
-
Krakow, Poland, 31-531
-
Ustron, Poland, 43-450
-
Warszawa, Poland, 02-637
-
Warszawa, Poland, 00-909
-
Wroclaw, Poland, 50-088
-
-
-
-
-
Barcelona, Spain, 08035
-
Madrid, Spain, 28006
-
Madrid, Spain, 28040
-
Madrid, Spain, 28046
-
Valencia, Spain, 46010
-
-
Cantabria
-
Santander, Cantabria, Spain, 39008
-
-
Madrid
-
Getafe, Madrid, Spain, 28902
-
-
Vizcaya
-
Bilbao, Vizcaya, Spain, 48013
-
-
-
-
-
Izmir, Turkey, 35340
-
-
-
-
-
Aintree, United Kingdom, L9 7AL
-
Newcastle, United Kingdom, NE7 7DN
-
Wirral, United Kingdom, CH49 5PE
-
-
Cambs
-
Cambridge, Cambs, United Kingdom, CB2 2QQ
-
-
West Midlands
-
Birmingham, West Midlands, United Kingdom, WS11 5XY
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Meet the 1987 ACR Revised Criteria for Rheumatoid Arthritis.
- Documented evidence, confirmed by a blinded 3rd party assessor, of at least one erosion observed by X-ray at randomization based on X-ray taken at the screening visit.
- Have received MTX as stable dose for 28 days prior to the screening visit.
Exclusion Criteria:
- Previous treatment with ETN, infliximab, adalimumab, other Tumor necrosis factor (TNF) -a inhibitors, anakinra or other biological agents.
- Receipt of any DMARD, other than MTX, within 28 days before screening.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Usual care
Utilized Disease-Modifying Antirheumatic Drugs (DMARDs) from a list of the 6 most commonly prescribed in the participating countries (Methotrexate, sulfasalazine, hydroxychloroquine, leflunomide, cyclosporine A and gold).
|
|
ACTIVE_COMPARATOR: ETN + MTX
Etanercept (ETN) 50 milligrams (mg) sub-cutaneous (SC) injection once weekly (pre-filled syringe) plus continuation of current dose of Methotrexate (MTX) either oral (PO), SC, or intramuscular (IM).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Modified Total Sharp Score (TSS) at Week 52
Time Frame: Baseline, Week 52
|
Modified TSS is a measure of change in joint health.
TSS is defined as joint space narrowing score (range 0 [no narrowing] to 168 [high narrowing]) plus (+) erosion score (range is from 0 [no erosion] to 280 [high erosion]).
The modified TSS range is from 0 (no damage) to 448 (bad joint status).
Increase from baseline represents disease progression and / or joint worsening; no change represents halting of disease progression; a decrease represents improvement.
|
Baseline, Week 52
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Erosions at Week 52
Time Frame: Baseline, Week 52
|
Erosion score (a component of the modified TSS) is a measure of change in joint health.
Erosion score range is from 0 (no erosion) to 280 (high erosion).
Increase from baseline represents disease progression and / or joint worsening; no change represents halting of disease progression; a decrease represents improvement.
|
Baseline, Week 52
|
Change From Baseline in Joint Space Narrowing at Week 52
Time Frame: Baseline, Week 52
|
Joint space narrowing score (a component of the modified TSS) is a measure of change in joint health.
Joint space narrowing score range is 0 (no narrowing) to 168 (high narrowing).
Increase from baseline represents disease progression and / or joint worsening; no change represents halting of disease progression; a decrease represents improvement.
|
Baseline, Week 52
|
Percentage of Participants Showing no Radiographic Progression (TSS Change <0.5) at Week 52
Time Frame: Baseline, Week 52, Last observation carried forward (LOCF)
|
Radiographic non-progression determined based on TSS change <0.5 using the dichotomous response Yes / No.
The modified TSS range is from 0 (no damage) to 448 (bad joint status).
Increase from baseline represents disease progression and / or joint worsening; no change represents halting of disease progression; a decrease represents improvement.
|
Baseline, Week 52, Last observation carried forward (LOCF)
|
Percentage of Participants Achieving >1.2 Improvement in Disease Activity Score Based on a 28-joint Count (DAS28)
Time Frame: Baseline, Week 12, Week 24, and Week 52
|
Disease activity score based on 28 painful joint counts, 28 swollen joint counts, erythrocyte sedimentation rate (ESR) in millimeters per hour (mm/hr), and general health (GH) using Visual Analog Scale (VAS); range 0 (very well) to 100 (extremely bad).
DAS28 score calculated as 0.56 square root (√) (28 painful joint count) + 0.28 √ (28 swollen joint count) + 0.70 (ln ESR mm/hr) + 0.014 GH; range 0 to 10. DAS28 score >5.1=higher disease activity; <3.2=low disease activity; <2.6=clinical remission.
Achievement of >1.2 improvement defined as decrease in DAS28 >1.2 (change in DAS28 < -1.2).
|
Baseline, Week 12, Week 24, and Week 52
|
Percentage of Participants Achieving Remission (DAS28 <2.60)
Time Frame: Week 12, Week 24, and Week 52
|
Disease activity score based on 28 painful joint counts, 28 swollen joint counts, erythrocyte sedimentation rate (ESR) mm/hr, and general health (GH) using a visual analog scale (VAS); VAS range: 0 (very well) to 100 (extremely bad).
DAS28 score calculated as 0.56 √ (28 painful joint count) + 0.28 √ (28 swollen joint count) + 0.70 (ln ESR mm/hr) + 0.014 GH; range 0 to 10. DAS28 score >5.10=higher disease activity; <3.20=low disease activity; <2.60=clinical remission.
|
Week 12, Week 24, and Week 52
|
Percentage of Participants Achieving Low Disease Activity (DAS28 ≤3.20)
Time Frame: Week 12, Week 24, and Week 52
|
Disease activity score based on 28 painful joint counts, 28 swollen joint counts, erythrocyte sedimentation rate (ESR) mm/hr, and general health (GH) using a visual analog scale (VAS); VAS range: 0 (very well) to 100 (extremely bad).
DAS28 score calculated as 0.56 √ (28 painful joint count) + 0.28 √ (28 swollen joint count) + 0.70 (ln ESR mm/hr) + 0.014 GH; range 0 to 10. DAS28 score >5.10=higher disease activity; <3.20=low disease activity; <2.60=clinical remission.
|
Week 12, Week 24, and Week 52
|
Percentage of Participants Achieving a >0.6 Disease Activity Score (DAS)28 Response
Time Frame: Week 12, Week 24, and Week 52
|
Disease activity score based on 28 painful joint counts, 28 swollen joint counts, erythrocyte sedimentation rate (ESR) mm/hr, and participant's assessment of general health (GH) using a visual analog scale (VAS); VAS range: 0 (very well) to 100 (extremely bad).
DAS28 score calculated as 0.56 √ (28 painful joint count) + 0.28 √ (28 swollen joint count) + 0.70 (ln ESR mm/hr) + 0.014 GH; range 0 to 10. DAS28 score >5.10=higher disease activity; <3.20=low disease activity; <2.60=clinical remission.
DAS28 response of >0.6 defined as decrease in DAS28 >0.6 (change in DAS28 < -0.6).
|
Week 12, Week 24, and Week 52
|
Percentage of Participants Achieving Moderate or Good Response on European League Against Rheumatism (EULAR) Response Criteria
Time Frame: Week 12, Week 24, Week 52
|
Response to treatment assessed by EULAR response criteria.
Participants were characterized as good, moderate, or non-responders based on both Disease Activity Score (DAS) level attained and change in DAS.
Good response defined as >1.2 improvement in DAS from Baseline and DAS attained during follow-up of ≤2.4.
Non-responders = participants with improvement of ≤0.6 or participants with improvement of >0.6 but ≤1.2 and DAS attained during follow-up of >5.1.
Remaining participants were classified as moderate.
Scores of good and moderate were considered to have therapeutic response.
|
Week 12, Week 24, Week 52
|
Percentage of Participants With American College of Rheumatology 20% (ACR20) Response
Time Frame: Week 12, Week 24, Week 52
|
American College of Rheumatology 20% (ACR20) response: responder = ≥ 20% improvement in tender joint count; ≥ 20% improvement in swollen joint count; and ≥ 20% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and erythrocyte sedimentation rate (ESR).
Subjects withdrawing early were non-responders.
|
Week 12, Week 24, Week 52
|
Percentage of Participants With American College of Rheumatology 50% (ACR50) Response
Time Frame: Week 12, Week 24, Week 52
|
American College of Rheumatology 50% (ACR50) response: responder = ≥ 50% improvement in tender joint count; ≥ 50% improvement in swollen joint count; and ≥ 50% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and erythrocyte sedimentation rate (ESR).
Subjects withdrawing early were non-responders.
|
Week 12, Week 24, Week 52
|
Percentage of Participants With American College of Rheumatology 70% (ACR70) Response
Time Frame: Week 12, Week 24, Week 52
|
American College of Rheumatology 70% (ACR70) response: responder = ≥ 70% improvement in tender joint count; ≥ 70% improvement in swollen joint count; and ≥ 70% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and erythrocyte sedimentation rate (ESR) .
Subjects withdrawing early were non-responders.
|
Week 12, Week 24, Week 52
|
Percentage of Participants With American College of Rheumatology 90% (ACR90) Response
Time Frame: Week 12, Week 24, Week 52
|
American College of Rheumatology 90% (ACR 90) response: responder = ≥ 90% improvement in tender joint count; ≥ 90% improvement in swollen joint count; and ≥ 90% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and erythrocyte sedimentation rate (ESR).
Subjects withdrawing early were non-responders.
|
Week 12, Week 24, Week 52
|
Change From Baseline in Mean Daily Dose of Corticosteroids to Manage Flare-ups Across the 52-week Treatment Period
Time Frame: Week 4, Week 12, Week 24, Week 40, Week 52
|
Mean daily dose of corticosteroids to manage flare-ups (temporary increases in corticosteroid dose or use of intra-articular steroids) during treatment period.
Daily dose of equivalent prednisone derived in mg/day: oral corticosteroids: 5 mg of prednisone = 5 mg of prednisolone = 25 mg of cortisone = 20 mg of hydrocortisone = 4 mg of methylprednisolone = 4 mg of triamcinolone = 2mg of paramethasone = 0.75 mg of betamethasone = 0.75 of dexamethasone = 0.3 of cortivazol.
|
Week 4, Week 12, Week 24, Week 40, Week 52
|
Percentage of Participants Achieving a Minimal Clinically Important Improvement (MCII)
Time Frame: Week 12, Week 52
|
Participants were asked how their pain had been during the last 48 hours compared to baseline.
Participants that reported improvement assessed how important this improvement was to them; range: very important, moderately important, slightly important, or not at all important.
Binary response options: 1=improved very important, or improved moderately important; 2=slightly important, not at all important, no change, or worse-more pain.
|
Week 12, Week 52
|
Percentage of Participants Achieving a Patient Acceptable Symptom State (PASS)
Time Frame: Week 4, Week 12, Week 24, Week 40, Week 52
|
Percentage of participants reporting acceptable symptom state: acceptance to remain for the rest of their lives with the level of pain they had during the last 48 hours; and unacceptable symptom state: not able to remain for the rest of their lives with the level of pain they had during the last 48 hours.
|
Week 4, Week 12, Week 24, Week 40, Week 52
|
Health Related Quality of Life: EuroQol-5D Health Index
Time Frame: Baseline, Week 12, Week 24, and Week 52
|
EQ-5D is a self-administered questionnaire to assess health-related quality of life in 5 domains (mobility, self care, usual activities, pain or discomfort, and anxiety or depression).
Scores from the 5 domains are used to calculate the Health State Profile Score as a single index value; range: 0.0 (death) to 1.0 (perfect health); higher scores indicate a better health state.
|
Baseline, Week 12, Week 24, and Week 52
|
Health Related Quality of Life: EuroQol-5D Health State Visual Analog Scale (VAS)
Time Frame: Baseline, Week 12, Week 24, and Week 52
|
EQ-5D: subject rated questionnaire to assess health-related quality of life in terms of a single index value.
The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state.
|
Baseline, Week 12, Week 24, and Week 52
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Mandl P, Balint PV, Brault Y, Backhaus M, D'Agostino MA, Grassi W, van der Heijde D, de Miguel E, Wakefield RJ, Logeart I, Dougados M. Clinical and ultrasound-based composite disease activity indices in rheumatoid arthritis: results from a multicenter, randomized study. Arthritis Care Res (Hoboken). 2013 Jun;65(6):879-87. doi: 10.1002/acr.21913.
- Mandl P, Balint PV, Brault Y, Backhaus M, D'Agostino MA, Grassi W, van der Heijde D, de Miguel E, Wakefield RJ, Logeart I, Dougados M. Metrologic properties of ultrasound versus clinical evaluation of synovitis in rheumatoid arthritis: results of a multicenter, randomized study. Arthritis Rheum. 2012 Apr;64(4):1272-82. doi: 10.1002/art.33491. Epub 2011 Nov 30.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2008
Primary Completion (ACTUAL)
December 1, 2009
Study Completion (ACTUAL)
May 1, 2010
Study Registration Dates
First Submitted
June 25, 2008
First Submitted That Met QC Criteria
June 27, 2008
First Posted (ESTIMATE)
June 30, 2008
Study Record Updates
Last Update Posted (ESTIMATE)
June 21, 2011
Last Update Submitted That Met QC Criteria
June 16, 2011
Last Verified
June 1, 2011
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Immune System Diseases
- Autoimmune Diseases
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Connective Tissue Diseases
- Arthritis
- Arthritis, Rheumatoid
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Gastrointestinal Agents
- Dermatologic Agents
- Reproductive Control Agents
- Abortifacient Agents, Nonsteroidal
- Abortifacient Agents
- Folic Acid Antagonists
- Etanercept
- Methotrexate
Other Study ID Numbers
- 0881X1-4437
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rheumatoid Arthritis
-
Janssen Research & Development, LLCWithdrawnActive Rheumatoid Arthritis; Rheumatoid Arthritis
-
Centocor, Inc.CompletedRheumatoid Arthritis, Juvenile
-
AmgenTerminated
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenImmunex CorporationCompletedJuvenile Rheumatoid Arthritis
-
National Institute of Arthritis and Musculoskeletal...Children's Hospital Medical Center, CincinnatiCompleted
-
University of PittsburghNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedRheumatoid Arthritis | Juvenile Rheumatoid ArthritisUnited States
-
University of Missouri-ColumbiaCompletedJuvenile Rheumatoid ArthritisUnited States
-
Assistance Publique - Hôpitaux de ParisSociete Francaise de RhumatologieRecruiting
-
Amsterdam UMC, location VUmcEuropean CommissionCompletedRheumatoId ArthritisNetherlands, Germany, Portugal, Italy, Hungary, Romania, Slovakia
Clinical Trials on methotrexate
-
University Hospital, MontpellierPfizer; Hôpital CochinCompletedRheumatoid ArthritisFrance, Monaco
-
Nicolaus Copernicus UniversityCompleted
-
Amneal Pharmaceuticals, LLCAccutest Research Laboratories (I) Pvt. Ltd.Unknown
-
Hee Young JuNot yet recruitingLymphoblastic Leukemia in Children
-
PfizerCompletedRheumatoid ArthritisUnited States, Mexico, Argentina, Chile, Croatia, Czech Republic, Hungary, Poland, Puerto Rico
-
PfizerCompletedRhematoid ArthritisSpain, United Kingdom, United States, Korea, Republic of, Poland, Israel, Australia, Taiwan, Thailand, South Africa, Bulgaria, Estonia, Latvia, Philippines, Canada, Romania, Russian Federation, Turkey, Mexico, Bosnia and Herzegovina and more
-
Cairo UniversityCompleted
-
Chugai Pharma TaiwanCompletedRheumatoid Arthritis (RA)Taiwan
-
CHA UniversityCompleted
-
Czech Lymphoma Study GroupUnknownDiffuse Large B-cell LymphomaCzech Republic